Please assess the completion status of the following clinical trial:

Trial Title: Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to adhere to medication regimen~* Speaks English~* Assigned female at birth with intact ovaries~* Premenopausal~* Normal menstrual cycles between 25-35 days~* Under current care of an outpatient mental health provider with visits occurring at least once every 3 months.~* At least 1 year postpartum.~* Willing to use a barrier method of birth control during the study.~* Normal weight (BMI between 18.00-29.99)~* Must report at least some recent suicidal ideation (in the past month) at the time of recruitment.~* Must be categorized as having acceptably low imminent risk for suicidal crisis/attempt by a licensed clinical psychologist utilizing evidence-based clinical and research guidelines for imminent suicide risk management.~Exclusion Criteria:~* Must not be pregnant, breastfeeding, or trying to become pregnant.~* Must not be taking any form of exogenous hormones or hormonal intrauterine device, and must have ended previous use of hormonal preparations at least one month prior to the study.~* Must not have a personal history of any chronic medical condition that may interfere with the aims of the study or make the experimental protocol unsafe, including but not limited to metabolic or autoimmune disease, epilepsy, endometriosis, cancer, diabetes, cardiovascular, gastrointestinal, hepatic, renal, or pulmonary disease, and no personal or first degree family history of thromboembolic events.~* Any current cigarette smoking is exclusionary.~* Must not report a current diagnosis of major depressive episode with peripartum onset (current episode), and must not be currently receiving treatment for premenstrual dysphoric disorder (Note: Premenstrual Dysphoric Disorder diagnosis must have been made based on prospective daily ratings).~* Must not report any history of manic episode, any history of psychotic symptoms, or current substance use disorder.~* Must not test positive for (unprescribed) opioid use, methamphetamine use, or cocaine use at the start of an experimental condition.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Transdermal Estradiol + Placebo (Type: EXPERIMENTAL): .1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
- Oral Micronized Progesterone + Placebo (Type: EXPERIMENTAL): 100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
- Placebos (Type: PLACEBO_COMPARATOR): Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).